Disclosure of Intangible Assets in Indian Drugs and Pharmaceutical Industry

Subhash Chander and Vishakha Mehra

The IUP Journal of Accounting Research and Audit Practices, 2010, vol. IX, issue 4, 7-23

Abstract: In ‘K-economy’, intangible assets are playing an important role in the creation and maximization of wealth of shareholders. The investors also attach greater significance to such assets in evaluating their investments in different companies. This study examines the voluntary disclosure practices of intangible assets of 50 companies in Indian drugs and pharmaceutical industry. Annual reports of the selected companies for the year 2007-08 have been used for the purpose of this study. Content analysis technique has been adopted for the purpose of studying the disclosure of intangible asset information, which has been categorized into human capital, external capital and internal capital. The study concludes that number of employees, training and development, market share, brands, research activities and patents are among the highly disclosed intangible asset attributes. From among the three categories, human capital is the most disclosed intangible asset category. Panacea Biotec Ltd., is the company with highest disclosure score of 73%. Overall disclosure of intangible assets is inadequate and unsystematic in India and there is a vast scope for improvement.

Date: 2010
References: Add references at CitEc
Citations: View citations in EconPapers (2)

There are no downloads for this item, see the EconPapers FAQ for hints about obtaining it.

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:icf:icfjar:v:09:y:2010:i:4:p:7-23

Access Statistics for this article

More articles in The IUP Journal of Accounting Research and Audit Practices from IUP Publications
Bibliographic data for series maintained by G R K Murty ().